Table 3.

Changes in secondary endpoints from baseline to week 24.

PARAMETER	LIRAGLUTIDE			SITAGLIPTIN			P-VALUE‡
	n*	CHANGE FROM BASELINE	P-VALUE†	n*	CHANGE FROM BASELINE	P-VALUE†
Body weight (kg)	36	−0.60 ± 2.44	0.1513	38	0.29 ± 2.05	0.3848	0.0969
BMI (kg/m2)	36	−0.23 ± 0.98	0.167	38	0.11 ± 0.78	0.3784	0.1027
FPG (mg/dL)	46	−21.15 ± 31.22	<0.0001	41	0.46 ± 39.39	0.9403	0.0014
F-IRI (μU/mL)	46	0.68 ± 3.39	0.183	42	1.46 ± 9.35	0.3178	0.5771
F-proinsulin (μU/mL)	46	1.06 ± 16.79	0.671	42	2.75 ± 20.64	0.393	0.683
HOMA-R	46	−0.17 ± 1.54	0.4619	41	1.12 ± 7.07	0.3166	0.2108
HOMA-β	46	26.18 ± 73.64	0.02	41	6.01 ± 33.75	0.2612	0.0944
Proinsulin/insulin ratio	46	−0.26 ± 2.28	0.4377	42	−1.07 ± 6.64	0.3008	0.7114
CPR (ng/mL)	46	0.21 ± 0.50	0.0073	42	0.09 ± 0.93	0.5277	0.4162
NT-proBNP (pg/mL)	46	−6.91 ± 42.04	0.2707	42	1.05 ± 60.71	0.9115	0.6202
Log-hsCRP	46	0.01 ± 1.40	0.9631	42	0.26 ± 1.18	0.1603	0.7435
PAID total score	39	−2.41 ± 7.97	0.1026	35	−2.97 ± 15.67	0.2829	0.7286

Notes:

^*The number of patients differs between each parameter because data are shown only for patients with data for the individual parameter at Week 24 and the last observation was not carried forward to impute missing data.

^†Versus baseline (paired t-test, except PAID total score [Wilcoxon signed-rank test]).

^‡For liraglutide versus sitagliptin (ANCOVA, except PAID total score [Wilcoxon rank-sum test]). Values are means ± standard deviation.

Abbreviations: BMI, body mass index; FPG, fasting plasma glucose; F-IRI, fasting immunoreactive insulin; F-proinsulin, fasting proinsulin; HOMA-R, homeostatic model assessment of insulin resistance; HOMA-β, homeostatic model assessment of β cell function; CPR, C-peptide immunoreactivity; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; hsCRP, high-sensitivity C-reactive protein; PAID, problem areas in diabetes survey.